<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303483</url>
  </required_header>
  <id_info>
    <org_study_id>44081</org_study_id>
    <nct_id>NCT02303483</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin B3 on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men</brief_title>
  <official_title>The Effect of Nicotinamide Ribose (NR) on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men - a Randomized, Placebo Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In animals, treatment with vitamin B3 improved insulin sensitivity and substrate metabolism.
      It is currently not know if vitamin B3 has the same positive effects in humans. In the
      current study the effect of a 3 month treatment with vitamin B3 on insulin sensitivity and
      substrate metabolism in obese men will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2016</start_date>
  <completion_date type="Actual">April 4, 2017</completion_date>
  <primary_completion_date type="Actual">April 4, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Change from baseline in insulin sensitivity at 3 months</time_frame>
    <description>determined by a hyperinsulineamic clamp</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Substrate metabolism</measure>
    <time_frame>Change from baseline in substrate metabolism at 3 months</time_frame>
    <description>measured by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition</measure>
    <time_frame>Change from baseline in body composition at 3 months</time_frame>
    <description>measured by DEXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activation of satellite cells</measure>
    <time_frame>Change from baseline in activation of satellite cells at 3 months</time_frame>
    <description>measured by immunohistochemestry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid accumulation in liver and skeletal muscle tissue</measure>
    <time_frame>Change from baseline in liver and muscle lipid content at 3 months</time_frame>
    <description>determined by MR-spectroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucose turnover</measure>
    <time_frame>Change from baseline in glucose turnover at 3 months</time_frame>
    <description>determined by glucose tracer techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin signalling in skeletal muscle and adipose tissue biopsies</measure>
    <time_frame>Change from baseline in insulin signaling at 3 months</time_frame>
    <description>western blotting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palmitate turnover</measure>
    <time_frame>Change from baseline in palmitate turnover at 3 months</time_frame>
    <description>determined by palmitate tracer techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota</measure>
    <time_frame>Change from baseline in composition of gut microbiota at 3 months</time_frame>
    <description>Intestinal bacteria composition by whole genome sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incretin hormone secretion</measure>
    <time_frame>Change from baseline in incretion hormone secretion at 3 months</time_frame>
    <description>Determined by measurement of incretin homones during an oral glucose tolerance test (OGTT)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Obese</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>lime tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotinamide riboside (NR, Vit B3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NIAGEN (ChromaDex) 1 g x 2 orally per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )</intervention_name>
    <arm_group_label>Nicotinamide riboside (NR, Vit B3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  written signed consent

          -  male

          -  BMI&gt;30 kg/(m2)

          -  age: 40-70

          -  no medication

          -  non-smoker

        Exclusion Criteria:

          -  endocrine disease

          -  other severe disease

          -  high daily activity level (&gt;30 min / day)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole Dollerup, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Novo Nordisk Foundation Center for Basic Metabolic Research, Integrative Physiology, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research Laboratories, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2014</study_first_posted>
  <last_update_submitted>June 29, 2017</last_update_submitted>
  <last_update_submitted_qc>June 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Ole Dollerup</investigator_full_name>
    <investigator_title>MD, PhD-student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

